Dr. Gomella on Sequencing Prostate Cancer Therapies

Leonard G. Gomella, MD
Published: Monday, Mar 25, 2013

Leonard G. Gomella, MD, professor and chair of the Department of Urology at the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer (mCRPC).

Gomella believes that researchers will be studying optimal therapeutic sequences in mCRPC for 3 to 5 years. Several agents have been recently approved and many more are still awaiting approval. At this point, Gomella adds, data are not available to support an optimal sequence, with one caveat, sipuleucel-T (Provenge).

Overall, Gomella notes, a consensus is emerging that sipuleucel-T should be administered earlier in asymptomatic patients who have recently been diagnosed with metastatic disease. Outside of sipuleucel-T, Gomella notes, researchers are still examining the optimal sequence for other recently approved agents, including cabazitaxel (Jevtana), abiraterone acetate (Zytiga), and enzalutamide (Xtandi).

Leonard G. Gomella, MD, professor and chair of the Department of Urology at the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer (mCRPC).

Gomella believes that researchers will be studying optimal therapeutic sequences in mCRPC for 3 to 5 years. Several agents have been recently approved and many more are still awaiting approval. At this point, Gomella adds, data are not available to support an optimal sequence, with one caveat, sipuleucel-T (Provenge).

Overall, Gomella notes, a consensus is emerging that sipuleucel-T should be administered earlier in asymptomatic patients who have recently been diagnosed with metastatic disease. Outside of sipuleucel-T, Gomella notes, researchers are still examining the optimal sequence for other recently approved agents, including cabazitaxel (Jevtana), abiraterone acetate (Zytiga), and enzalutamide (Xtandi).




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x